openPR Logo
Press release

Investigation announced for Investors who lost money with NASDAQ: AXSM shares over potential Wrongdoing at Axsome Therapeutics, Inc.

04-18-2023 05:35 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares over potential wrongdoing.

An investigation on behalf of investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Axsome Therapeutics, Inc.

Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Axsome Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

The lawsuit against certain directors comes after a lawsuit was filed against Axsome Therapeutics, Inc. over alleged Securities Laws violations. According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the defendants made false and/or misleading statements and/or failed to disclose that Axsome's CMC practices were deficient with respect to AXS-07 and its manufacturing process, that as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline, that the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA, that accordingly, the FDA was unlikely to approve the AXS-07 NDA, that as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors who lost money with NASDAQ: AXSM shares over potential Wrongdoing at Axsome Therapeutics, Inc. here

News-ID: 3017061 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: TMCI) over potential Wrongdoing
Investigation announced for Investors in Treace Medical Concepts, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Treace Medical Concepts, Inc. Investors who purchased shares of Treace Medical Concepts, Inc. (NASDAQ: TMCI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Treace Medical Concepts, Inc. directors breached their fiduciary duties and caused damage to the company and its
Deadline on May 20th coming up in Lawsuit for Investors in the Chemours Company (NYSE: CC)
Deadline on May 20th coming up in Lawsuit for Investors in the Chemours Company …
A deadline is coming up on May 20, 2024 in the lawsuit filed for certain investors of The Chemours Company (NYSE: CC) over alleged securities laws violations by The Chemours Company. Investors who purchased shares of The Chemours Company (NYSE: CC) have certain options and there are strict and short deadlines running. Deadline: May 20, 2024. NYSE: CC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Lawsuit filed for certain Investors who lost money with shares of Global Cord Blood Corporation (OTC: CORBF)
Lawsuit filed for certain Investors who lost money with shares of Global Cord Bl …
An investor, who purchased shares of Global Cord Blood Corporation (OTC: CORBF), filed a lawsuit over alleged violations of Federal Securities Laws by Global Cord Blood Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Global Cord Blood Corporation (OTC: CORBF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. OTC: CORBF investors should contact the Shareholders
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ: ADSK)
Lawsuit filed for Investors who lost money with shares of Autodesk, Inc. (NASDAQ …
An investor, who purchased shares of Autodesk, Inc. (NASDAQ: ADSK), filed a lawsuit over alleged violations of Federal Securities Laws by Autodesk, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Autodesk, Inc. (NASDAQ: ADSK) have certain options and for certain investors are short and strict deadlines running. Deadline: June 24, 2024. NASDAQ: ADSK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Axsome

Investigation announced for NASDAQ: AXSM Investors over possible Wrongdoing at A …
An investigation was announced for clong-term investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) concerning potential breaches of fiduciary duties by certain directors and officers of Axsome Therapeutics, Inc. Investors who are current long term investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on July 12, 2022 coming up in Lawsuit for Investors in Axsome Therapeut …
A deadline is coming up on July 12, 2022 in the lawsuit filed for certain investors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) over alleged securities laws violations by Axsome Therapeutics, Inc. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and there are strict and short deadlines running. Deadline: July 12, 2022. NASDAQ: AXSM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Lawsuit filed for Investors in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM …
An investor, who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Axsome Therapeutics, Inc. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and for certain investors are short and strict deadlines running. Deadline: July 12, 2022. NASDAQ: AXSM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. New
Investigation announced for Long-Term Investors in Axsome Therapeutics, Inc. (NA …
Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Axsome Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders. New York based Axsome Therapeutics,
Investigation announced for Investors in shares of Axsome Therapeutics, Inc. (NA …
An investigation was announced over potential securities laws violations by Axsome Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Axsome Therapeutics, Inc. regarding its business, its prospects and its operations were
Depression - Pipeline Review & Swot Analysis by key Manufacturers Atai Life Scie …
A new independent 668 page research with title 'Depression - Pipeline Review, H1 2020' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, South America, Asia & Pacific, Europe & MEA (Middle East and Africa) and important players/vendors such as Acadia Pharmaceuticals Inc, Adamed Sp zoo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aision Biotechnologies Inc, Alkermes Plc etc.